Pre-Case Assessment: Test Your Baseline Knowledge
Answer these questions before reviewing the case to assess your starting knowledge of hemodynamics, ascites evaluation, and cardiac physiology.
1
A patient has a cardiac index of 1.8 L/min/m² and a PCWP of 24 mmHg. Which Forrester hemodynamic profile does this represent?
A) Profile A -- warm and dry (CI >2.2, PCWP <18)
B) Profile B -- warm and wet (CI >2.2, PCWP >18)
C) Profile C -- cold and wet (CI <2.2, PCWP >18)
D) Profile L -- cold and dry (CI <2.2, PCWP <18)
Correct Answer: C
Learning Point: Forrester Profile C ("cold and wet") indicates low cardiac output with elevated filling pressures -- the worst prognosis subset. CI <2.2 L/min/m² defines "cold" (hypoperfusion) and PCWP >18 mmHg defines "wet" (congestion). This profile carries the highest in-hospital mortality (~50%) and demands urgent intervention with inotropes and/or mechanical circulatory support.
📚 Learn More: RHC Comprehensive Interpretation Guide
Learning Point: Forrester Profile C ("cold and wet") indicates low cardiac output with elevated filling pressures -- the worst prognosis subset. CI <2.2 L/min/m² defines "cold" (hypoperfusion) and PCWP >18 mmHg defines "wet" (congestion). This profile carries the highest in-hospital mortality (~50%) and demands urgent intervention with inotropes and/or mechanical circulatory support.
📚 Learn More: RHC Comprehensive Interpretation Guide
2
Which of the following cardiac index values is consistent with cardiogenic shock?
A) 2.8 L/min/m²
B) 2.2 L/min/m²
C) 1.9 L/min/m²
D) 1.15 L/min/m²
Correct Answer: D
Learning Point: Normal CI is 2.5-4.0 L/min/m². A CI <2.2 indicates low output; a CI <1.8 is consistent with cardiogenic shock. A CI of 1.15 L/min/m² -- as seen in Patient A -- is profoundly reduced and life-threatening. This degree of output reduction was present despite an EF of 55%, illustrating that ejection fraction alone cannot assess cardiac output adequacy.
📚 Learn More: RHC Comprehensive Interpretation Guide
Learning Point: Normal CI is 2.5-4.0 L/min/m². A CI <2.2 indicates low output; a CI <1.8 is consistent with cardiogenic shock. A CI of 1.15 L/min/m² -- as seen in Patient A -- is profoundly reduced and life-threatening. This degree of output reduction was present despite an EF of 55%, illustrating that ejection fraction alone cannot assess cardiac output adequacy.
📚 Learn More: RHC Comprehensive Interpretation Guide
3
A patient with ascites has SAAG 1.7 g/dL and ascitic fluid total protein 3.9 g/dL. Which of the following is the MOST likely etiology?
A) Alcoholic cirrhosis
B) Cardiac ascites (right heart failure)
C) Peritoneal carcinomatosis
D) Nephrotic syndrome
Correct Answer: B
Learning Point: SAAG >= 1.1 g/dL indicates portal hypertension physiology. The high ascitic fluid protein (>= 2.5 g/dL) is the critical differentiator: cirrhotic ascites produces LOW-protein fluid (<2.5 g/dL) because sinusoidal capillarization blocks protein passage, while cardiac ascites produces HIGH-protein fluid (>= 2.5 g/dL) because hepatic sinusoidal fenestrations remain intact. Peritoneal carcinomatosis has low SAAG (<1.1); nephrotic syndrome has low SAAG and low protein.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
Learning Point: SAAG >= 1.1 g/dL indicates portal hypertension physiology. The high ascitic fluid protein (>= 2.5 g/dL) is the critical differentiator: cirrhotic ascites produces LOW-protein fluid (<2.5 g/dL) because sinusoidal capillarization blocks protein passage, while cardiac ascites produces HIGH-protein fluid (>= 2.5 g/dL) because hepatic sinusoidal fenestrations remain intact. Peritoneal carcinomatosis has low SAAG (<1.1); nephrotic syndrome has low SAAG and low protein.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
Case Presentation: Patient A
A 75-year-old man with no liver disease risk factors was referred to nephrology following recurrent massive ascites. He denied alcohol use, viral hepatitis exposure, and autoimmune disease. He was on chronic warfarin anticoagulation for an unrelated indication.
Initial workup:
- Abdominal and pelvic CT: micronodular liver changes interpreted as cirrhosis with portal hypertension
- Echocardiography: LVEF 55% with mild RVSP elevation (estimated 40 mmHg)
- Serum albumin: 4.0 g/dL (normal synthetic function)
- Total bilirubin: 1.7 mg/dL; INR 4.0 (supratherapeutic on warfarin -- not hepatic failure)
- Paracentesis: 5.7 liters removed; ascitic fluid protein 3.6-4.1 g/dL; SAAG 1.7 g/dL
- No peripheral lower extremity edema despite massive, rapidly recurrent ascites
Diuretic therapy at presentation: Bumetanide 4 mg BID (~furosemide 320 mg/day), dapagliflozin 10 mg daily, spironolactone 50 mg daily. Despite this near-maximal triple-agent regimen, ascites reaccumulated within days.
Right Heart Catheterization Results
| Parameter | Measured Value | Normal Range | Significance |
|---|---|---|---|
| RA pressure | 23 mmHg | 0-8 mmHg | Explains refractory ascites |
| RV pressure | 43/25 mmHg | 15-30/0-8 mmHg | Biventricular failure |
| PA pressure (sys/dias) | 54/34 mmHg | 15-30/4-12 mmHg | Moderate-severe PH |
| PCWP | 28 mmHg | 4-12 mmHg | Severe diastolic dysfunction |
| Cardiac output | 2.66 L/min | 4.0-8.0 L/min | Severely reduced |
| Cardiac index | 1.15 L/min/m² | 2.5-4.0 L/min/m² | Cardiogenic shock range |
| SvO2 | 65% | 65-75% | At lower limit -- impending decompensation |
| Derived mPAP | 40.7 mmHg | 10-20 mmHg | Moderately severe PH |
| Derived PVR | 4.8 Wood units | 0.25-1.6 WU | Combined pre- and post-capillary PH |
| Forrester profile | C ("cold and wet") | A | Worst prognosis subset |
FLC and Monoclonal Protein Data
| Test | Result | Reference Range |
|---|---|---|
| Free kappa | 53.1 mg/L | 3.3-19.4 mg/L |
| Free lambda | 285 mg/L | 5.7-26.3 mg/L |
| Kappa/lambda ratio | 0.1863 | 0.26-1.65 |
| dFLC (lambda - kappa) | 231.9 mg/L | -- |
| Serum immunofixation | Positive -- IgA lambda | -- |
| Urine immunofixation | Positive -- lambda light chains | -- |
| M-protein (IgA lambda) | <0.010 g/dL | -- |
Clinical Reasoning: Analyze Patient A's Data
Use the hemodynamic and laboratory data above to answer these questions.
4
Patient A has a cardiac output of 2.66 L/min and a BSA of 2.31 m². His echocardiographic EF is 55%. Which statement BEST explains the discrepancy between a "normal" EF and cardiogenic shock-range CI?
A) The echocardiogram was technically inadequate and the EF is falsely elevated
B) The cardiac output measurement by thermodilution is unreliable in low-flow states
C) The ventricle ejects a normal fraction of a severely reduced end-diastolic volume (~60 mL instead of ~120 mL), producing a stroke volume of only ~33 mL
D) High afterload from pulmonary hypertension is preventing forward flow despite normal contractility
Correct Answer: C
Learning Point: EF = SV/EDV. If EDV is ~60 mL (half normal due to amyloid infiltration causing extreme stiffness) and SV is ~33 mL, then EF = 33/60 = 55%. The echo reads "normal ejection fraction." The patient is in cardiogenic shock. EF is preserved because there is less blood to eject, not because the heart is well. This is the defining hemodynamic trap of infiltrative cardiomyopathy.
📚 Learn More: Misleading Echocardiographic Findings in Infiltrative Cardiomyopathy
Learning Point: EF = SV/EDV. If EDV is ~60 mL (half normal due to amyloid infiltration causing extreme stiffness) and SV is ~33 mL, then EF = 33/60 = 55%. The echo reads "normal ejection fraction." The patient is in cardiogenic shock. EF is preserved because there is less blood to eject, not because the heart is well. This is the defining hemodynamic trap of infiltrative cardiomyopathy.
📚 Learn More: Misleading Echocardiographic Findings in Infiltrative Cardiomyopathy
5
Ladefoged et al. (2020) reported a median diagnostic delay in cardiac amyloidosis. What is this delay, and what percentage of cardiac amyloidosis patients are initially misdiagnosed according to Quarta et al. (2022)?
A) 6 months delay; 25% misdiagnosed
B) 13 months delay; 44% misdiagnosed
C) 18 months delay; 60% misdiagnosed
D) 24 months delay; 35% misdiagnosed
Correct Answer: B
Learning Point: Ladefoged et al. (2020) found a median diagnostic delay of 13 months from first manifestation to cardiac amyloidosis diagnosis. Quarta et al. (2022) found 44% of cardiac amyloidosis patients are initially misdiagnosed. A global survey of 1,460 physicians found only 10% performed systematic amyloidosis screening in HFpEF. This diagnostic delay is directly lethal in AL amyloidosis.
📚 Learn More: AL Amyloidosis and Multiple Myeloma
Learning Point: Ladefoged et al. (2020) found a median diagnostic delay of 13 months from first manifestation to cardiac amyloidosis diagnosis. Quarta et al. (2022) found 44% of cardiac amyloidosis patients are initially misdiagnosed. A global survey of 1,460 physicians found only 10% performed systematic amyloidosis screening in HFpEF. This diagnostic delay is directly lethal in AL amyloidosis.
📚 Learn More: AL Amyloidosis and Multiple Myeloma
6
Patient A's CT showed micronodular liver changes interpreted as cirrhosis. Which combination of findings should have triggered reconsideration of this diagnosis?
A) Elevated bilirubin + INR 4.0 + ascitic fluid protein 3.9 g/dL
B) SAAG 1.7 g/dL + low albumin + presence of varices
C) No liver disease risk factors + albumin 4.0 g/dL + ascitic fluid protein 3.6-4.1 g/dL + absence of peripheral edema
D) Micronodular changes + elevated RVSP + SAAG 1.7 g/dL
Correct Answer: C
Learning Point: Cardiac pseudo-cirrhosis occurs when RA pressure of 23 mmHg produces sustained hepatic venous congestion, causing centrilobular necrosis and compensatory nodular regeneration. The key distinguishing features are: (1) No liver disease risk factors; (2) Preserved synthetic function (albumin 4.0 g/dL); (3) High ascitic fluid protein >= 2.5 g/dL indicating intact sinusoidal fenestrations; (4) Absence of peripheral edema reflecting preferential splanchnic transudation. The INR of 4.0 was pharmacologic (warfarin), not hepatic failure.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
Learning Point: Cardiac pseudo-cirrhosis occurs when RA pressure of 23 mmHg produces sustained hepatic venous congestion, causing centrilobular necrosis and compensatory nodular regeneration. The key distinguishing features are: (1) No liver disease risk factors; (2) Preserved synthetic function (albumin 4.0 g/dL); (3) High ascitic fluid protein >= 2.5 g/dL indicating intact sinusoidal fenestrations; (4) Absence of peripheral edema reflecting preferential splanchnic transudation. The INR of 4.0 was pharmacologic (warfarin), not hepatic failure.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
7
Patient A has mPAP 40.7 mmHg, PCWP 28 mmHg, and PVR 4.8 Wood units. What is the correct PH classification, and what is the critical therapeutic implication?
A) Group 1 PAH -- start prostacyclin or endothelin receptor antagonist
B) Group 2 combined pre- and post-capillary PH (CpcPH) -- PAH-specific vasodilators are contraindicated
C) Group 3 PH due to lung disease -- pursue pulmonary function testing
D) Group 4 CTEPH -- refer for pulmonary thromboendarterectomy evaluation
Correct Answer: B
Learning Point: PCWP 28 mmHg (>15) confirms Group 2 (left heart disease). PVR 4.8 WU (>2) with elevated mPAP classifies this as CpcPH. PAH-specific vasodilator therapy is contraindicated -- pulmonary vasodilators increase pulmonary blood flow into an already congested left heart and can precipitate acute pulmonary edema. Treating Group 2 CpcPH as Group 1 PAH is among the most dangerous diagnostic errors in pulmonary hypertension management.
📚 Learn More: RHC Comprehensive Interpretation Guide
Learning Point: PCWP 28 mmHg (>15) confirms Group 2 (left heart disease). PVR 4.8 WU (>2) with elevated mPAP classifies this as CpcPH. PAH-specific vasodilator therapy is contraindicated -- pulmonary vasodilators increase pulmonary blood flow into an already congested left heart and can precipitate acute pulmonary edema. Treating Group 2 CpcPH as Group 1 PAH is among the most dangerous diagnostic errors in pulmonary hypertension management.
📚 Learn More: RHC Comprehensive Interpretation Guide
Interactive Timeline: Critical Decision Points
Patient A's diagnostic journey involved four converging traps. At each decision point below, select the correct reasoning.
Decision Point 1: The echocardiogram reports EF 55% with mild RVSP elevation. The clinical team concludes "normal cardiac function." What should have been the next step?
Trap 1: Preserved EF Masking Cardiogenic Shock
The correct next step is right heart catheterization. When clinical severity (refractory ascites on near-maximal diuretics) exceeds echo reassurance (EF 55%), RHC -- not additional echocardiographic views -- is the appropriate next step. EF is preserved because there is less blood to eject, not because the heart is well. The RHC revealed CI 1.15 L/min/m² -- cardiogenic shock range.
📚 Learn More: Misleading Echocardiographic Findings in Infiltrative Cardiomyopathy
The correct next step is right heart catheterization. When clinical severity (refractory ascites on near-maximal diuretics) exceeds echo reassurance (EF 55%), RHC -- not additional echocardiographic views -- is the appropriate next step. EF is preserved because there is less blood to eject, not because the heart is well. The RHC revealed CI 1.15 L/min/m² -- cardiogenic shock range.
📚 Learn More: Misleading Echocardiographic Findings in Infiltrative Cardiomyopathy
8
A 75-year-old with refractory ascites has EF 55% on echocardiography. The clinical team is reassured. Which additional data point should most urgently prompt right heart catheterization?
A) Mild RVSP elevation (40 mmHg)
B) Ascites refractory to bumetanide 4 mg BID + dapagliflozin + spironolactone
C) Serum albumin of 4.0 g/dL
D) CT showing micronodular liver changes
Correct Answer: B
Learning Point: Refractory ascites despite near-maximal triple diuretic therapy indicates a hemodynamic problem that echocardiography alone cannot characterize. The disconnect between clinical severity and echo reassurance is the strongest indication for invasive hemodynamic assessment. Mild RVSP elevation is nonspecific; albumin 4.0 argues against cirrhosis; CT findings may be misleading (pseudo-cirrhosis).
📚 Learn More: Misleading Echocardiographic Findings in Infiltrative Cardiomyopathy
Learning Point: Refractory ascites despite near-maximal triple diuretic therapy indicates a hemodynamic problem that echocardiography alone cannot characterize. The disconnect between clinical severity and echo reassurance is the strongest indication for invasive hemodynamic assessment. Mild RVSP elevation is nonspecific; albumin 4.0 argues against cirrhosis; CT findings may be misleading (pseudo-cirrhosis).
📚 Learn More: Misleading Echocardiographic Findings in Infiltrative Cardiomyopathy
Decision Point 2: The CT is read as cirrhosis. Should this diagnosis be accepted at face value?
Trap 2: Cardiac Pseudo-Cirrhosis on CT
No. The diagnostic combination -- SAAG >= 1.1 + fluid protein >= 2.5 + preserved albumin + no liver disease risk factors -- should prompt immediate cardiac evaluation. RA pressure of 23 mmHg produces sustained hepatic venous congestion, causing centrilobular hepatocellular necrosis and compensatory nodular regeneration that mimics cirrhosis on CT.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
No. The diagnostic combination -- SAAG >= 1.1 + fluid protein >= 2.5 + preserved albumin + no liver disease risk factors -- should prompt immediate cardiac evaluation. RA pressure of 23 mmHg produces sustained hepatic venous congestion, causing centrilobular hepatocellular necrosis and compensatory nodular regeneration that mimics cirrhosis on CT.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
9
In differentiating cirrhotic from cardiac ascites, which feature of the ascitic fluid is the MOST reliable distinguishing test?
A) SAAG value alone
B) Ascitic fluid total protein level (>= 2.5 g/dL favors cardiac etiology)
C) Ascitic fluid white blood cell count
D) Ascitic fluid glucose level
Correct Answer: B
Learning Point: Both cirrhotic and cardiac ascites have SAAG >= 1.1 (portal hypertension physiology), so SAAG alone cannot differentiate them. The key distinction is ascitic fluid protein: cirrhosis produces low-protein fluid (<2.5 g/dL) because sinusoidal capillarization closes fenestrations and blocks protein passage, while cardiac ascites produces high-protein fluid (>= 2.5 g/dL) because sinusoidal fenestrations remain intact.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
Learning Point: Both cirrhotic and cardiac ascites have SAAG >= 1.1 (portal hypertension physiology), so SAAG alone cannot differentiate them. The key distinction is ascitic fluid protein: cirrhosis produces low-protein fluid (<2.5 g/dL) because sinusoidal capillarization closes fenestrations and blocks protein passage, while cardiac ascites produces high-protein fluid (>= 2.5 g/dL) because sinusoidal fenestrations remain intact.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
Decision Point 3: Cardiac amyloidosis is now suspected. Should you order PYP scintigraphy first, or FLC/monoclonal protein screen first?
Critical Ordering Principle: Both must be ordered simultaneously. PYP scintigraphy cannot be interpreted without simultaneous monoclonal protein exclusion. A positive PYP in a patient with a monoclonal protein requires tissue biopsy with mass spectrometry. The most dangerous error is diagnosing ATTR on PYP alone and prescribing tafamidis when the patient actually has AL amyloidosis. In Stage III-IV AL cardiac amyloidosis, the therapeutic window is measured in weeks.
📚 Learn More: ATTR Cardiac Amyloidosis
📚 Learn More: ATTR Cardiac Amyloidosis
10
A patient has Grade 2 uptake on Tc-99m PYP scintigraphy. Serum immunofixation reveals a monoclonal IgG kappa band. What is the correct next step?
A) Diagnose ATTR-CM and start tafamidis
B) Perform endomyocardial biopsy with mass spectrometry typing to differentiate ATTR from AL
C) Repeat PYP scintigraphy in 3 months
D) Proceed with cardiac MRI for confirmation
Correct Answer: B
Learning Point: The Gillmore et al. (2016) nonbiopsy diagnostic algorithm for ATTR-CM requires Grade 2-3 PYP uptake AND absence of a monoclonal protein. When a monoclonal protein is present, PYP positivity is diagnostically ambiguous -- AL amyloidosis can produce PYP uptake, and the patient may have coexisting MGUS with ATTR. Tissue biopsy with mass spectrometry is mandatory to determine the amyloid fibril type. Prescribing tafamidis for undiagnosed AL is potentially lethal.
📚 Learn More: ATTR Cardiac Amyloidosis
Learning Point: The Gillmore et al. (2016) nonbiopsy diagnostic algorithm for ATTR-CM requires Grade 2-3 PYP uptake AND absence of a monoclonal protein. When a monoclonal protein is present, PYP positivity is diagnostically ambiguous -- AL amyloidosis can produce PYP uptake, and the patient may have coexisting MGUS with ATTR. Tissue biopsy with mass spectrometry is mandatory to determine the amyloid fibril type. Prescribing tafamidis for undiagnosed AL is potentially lethal.
📚 Learn More: ATTR Cardiac Amyloidosis
Decision Point 4: The FLC values are elevated (kappa 53.1, lambda 285). The clinical team dismisses both values as "CKD artifact." Is this correct?
Trap 4: FLC Values Dismissed as "CKD Artifact"
Incorrect. While absolute FLC values are physiologically elevated in CKD, renal failure elevates both kappa and lambda proportionally and does not preferentially drive one over the other. The kappa/lambda ratio of 0.1863 is far below both the standard lower limit (0.26) and the iStopMM eGFR-adjusted lower limit for this patient's CKD stage (~0.54 for eGFR <30). This ratio represents lambda clonal excess and is diagnostic signal, not physiologic noise.
📚 Learn More: Monoclonal Protein Interpretation for the Nephrologist
Incorrect. While absolute FLC values are physiologically elevated in CKD, renal failure elevates both kappa and lambda proportionally and does not preferentially drive one over the other. The kappa/lambda ratio of 0.1863 is far below both the standard lower limit (0.26) and the iStopMM eGFR-adjusted lower limit for this patient's CKD stage (~0.54 for eGFR <30). This ratio represents lambda clonal excess and is diagnostic signal, not physiologic noise.
📚 Learn More: Monoclonal Protein Interpretation for the Nephrologist
11
Patient A has confirmed lambda AL cardiac amyloidosis with dFLC 231.9 mg/L and CI 1.15 L/min/m². What is the single most important principle regarding the timing of the remaining diagnostic workup?
A) Sequential ordering is preferred to avoid unnecessary tests
B) Wait for hematology consultation before ordering bone marrow biopsy
C) All staging studies (bone marrow, NT-proBNP, troponin, PET) must be ordered simultaneously and urgently
D) Cardiac MRI should be performed before any hematologic workup
Correct Answer: C
Learning Point: In Stage III-IV AL cardiac amyloidosis, the therapeutic window is measured in weeks. Patient A died from sudden cardiac arrest during staging PET scanning before disease-modifying therapy could be initiated. The time between initial presentation and diagnostic confirmation was consumed by sequential rather than parallel diagnostic steps. Sequential ordering at this stage is not merely inefficient -- it is lethal.
📚 Learn More: AL Amyloidosis and Multiple Myeloma
Learning Point: In Stage III-IV AL cardiac amyloidosis, the therapeutic window is measured in weeks. Patient A died from sudden cardiac arrest during staging PET scanning before disease-modifying therapy could be initiated. The time between initial presentation and diagnostic confirmation was consumed by sequential rather than parallel diagnostic steps. Sequential ordering at this stage is not merely inefficient -- it is lethal.
📚 Learn More: AL Amyloidosis and Multiple Myeloma
Module Deep Dive: Pathophysiology and Diagnostic Frameworks
These questions test deeper understanding of AL amyloidosis pathophysiology, FLC interpretation in CKD, and ATTR vs AL differentiation.
12
Approximately 20-30% of AL amyloidosis patients present with cardiac-predominant disease and minimal renal involvement. What determines this tissue tropism?
A) The total mass of monoclonal protein produced by the plasma cell clone
B) The variable domain sequence of the light chain, particularly CDR1 and CDR3 loops, with V-lambda-1 and V-lambda-6 segments showing preferential cardiac tropism
C) The patient's age and pre-existing cardiac risk factors
D) The isotype of the intact immunoglobulin (IgG vs IgA vs IgM)
Correct Answer: B
Learning Point: Tissue tropism in AL amyloidosis is determined by the variable domain sequence of the light chain. Lambda light chains encoded by V-lambda-1 and V-lambda-6 germline variable region gene segments show strong preferential cardiac tropism, depositing in the myocardial interstitium, conduction system, and intramural coronary vasculature while largely sparing the glomerular capillary loops. This explains why Patient A had severe cardiac amyloidosis without nephrotic syndrome.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
Learning Point: Tissue tropism in AL amyloidosis is determined by the variable domain sequence of the light chain. Lambda light chains encoded by V-lambda-1 and V-lambda-6 germline variable region gene segments show strong preferential cardiac tropism, depositing in the myocardial interstitium, conduction system, and intramural coronary vasculature while largely sparing the glomerular capillary loops. This explains why Patient A had severe cardiac amyloidosis without nephrotic syndrome.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
13
Thorsteinsdottir et al. (Blood Cancer J, 2022) studied FLC reference intervals in CKD using the iStopMM cohort (6,461 participants with eGFR <60). Applying eGFR-adjusted reference intervals instead of standard intervals reduced the false-positive rate by what factor?
A) 3-fold (from 9% to 3%)
B) 5-fold (from 9% to 1.8%)
C) 13-fold (from 9% to 0.7%)
D) 20-fold (from 9% to 0.45%)
Correct Answer: C
Learning Point: Applying the standard reference interval (0.26-1.65) to CKD patients produces a 9% false-positive rate. Applying eGFR-adjusted intervals drops this to 0.7% -- a 13-fold reduction -- while maintaining sensitivity for true clonal disease. The practical framework: (1) Look at the ratio, not the absolutes; (2) Apply iStopMM eGFR-adjusted intervals; (3) A markedly low ratio (lambda excess, <0.2) with unexplained cardiac dysfunction is lambda AL amyloidosis until proven otherwise.
📚 Learn More: Monoclonal Protein Interpretation for the Nephrologist
Learning Point: Applying the standard reference interval (0.26-1.65) to CKD patients produces a 9% false-positive rate. Applying eGFR-adjusted intervals drops this to 0.7% -- a 13-fold reduction -- while maintaining sensitivity for true clonal disease. The practical framework: (1) Look at the ratio, not the absolutes; (2) Apply iStopMM eGFR-adjusted intervals; (3) A markedly low ratio (lambda excess, <0.2) with unexplained cardiac dysfunction is lambda AL amyloidosis until proven otherwise.
📚 Learn More: Monoclonal Protein Interpretation for the Nephrologist
14
Patient A's M-protein was essentially undetectable (<0.010 g/dL) by electrophoresis. In AL amyloidosis, what percentage of patients have a detectable M-spike on SPEP?
A) >90% -- SPEP is sufficient to screen for AL
B) ~75% -- add immunofixation to improve sensitivity
C) ~50% -- the FLC ratio is abnormal in >80% and is the primary AL screening tool
D) ~25% -- most AL patients have no detectable monoclonal protein by any method
Correct Answer: C
Learning Point: In AL amyloidosis, SPEP detects an M-spike in only ~50% of patients; the FLC ratio is abnormal in >80%. The monoclonal protein screen (SPEP/immunofixation/MASS-FIX) and the serum FLC ratio answer different questions. The monoclonal protein screen asks: does this patient have MGUS, MGRS, or myeloma? The FLC ratio asks: does this patient have AL amyloidosis? A clinician who relies on SPEP alone to screen for AL amyloidosis will miss approximately half of all cases.
📚 Learn More: Monoclonal Protein Interpretation for the Nephrologist
Learning Point: In AL amyloidosis, SPEP detects an M-spike in only ~50% of patients; the FLC ratio is abnormal in >80%. The monoclonal protein screen (SPEP/immunofixation/MASS-FIX) and the serum FLC ratio answer different questions. The monoclonal protein screen asks: does this patient have MGUS, MGRS, or myeloma? The FLC ratio asks: does this patient have AL amyloidosis? A clinician who relies on SPEP alone to screen for AL amyloidosis will miss approximately half of all cases.
📚 Learn More: Monoclonal Protein Interpretation for the Nephrologist
15
Patient A had Grade 0 uptake on Tc-99m PYP scintigraphy and a positive lambda monoclonal protein screen. What does this combination establish?
A) ATTR cardiac amyloidosis is confirmed -- start tafamidis
B) Neither ATTR nor AL can be diagnosed without endomyocardial biopsy
C) ATTR-CM is effectively excluded; the diagnosis is AL (lambda) cardiac amyloidosis
D) The PYP scan is falsely negative due to the low cardiac index
Correct Answer: C
Learning Point: Grade 0 PYP uptake effectively excludes ATTR-CM (sensitivity >99% for Grade >= 2 in ATTR). Combined with a positive lambda monoclonal protein screen and severely abnormal FLC ratio (0.1863), the diagnosis is AL (lambda) cardiac amyloidosis. Note: if PYP had been positive AND a monoclonal protein were present, tissue biopsy with mass spectrometry would be required -- the Gillmore nonbiopsy algorithm requires absence of monoclonal protein for a noninvasive ATTR diagnosis.
📚 Learn More: ATTR Cardiac Amyloidosis
Learning Point: Grade 0 PYP uptake effectively excludes ATTR-CM (sensitivity >99% for Grade >= 2 in ATTR). Combined with a positive lambda monoclonal protein screen and severely abnormal FLC ratio (0.1863), the diagnosis is AL (lambda) cardiac amyloidosis. Note: if PYP had been positive AND a monoclonal protein were present, tissue biopsy with mass spectrometry would be required -- the Gillmore nonbiopsy algorithm requires absence of monoclonal protein for a noninvasive ATTR diagnosis.
📚 Learn More: ATTR Cardiac Amyloidosis
Learning Objectives: Verify the 8 Teaching Points
These questions verify mastery of the case's core teaching points.
16
Which of the following statements about INR interpretation in Patient A is CORRECT?
A) INR 4.0 confirms coagulopathy from hepatic synthetic failure
B) INR and albumin should be used together -- both are equally affected by liver disease and warfarin
C) INR 4.0 on warfarin is pharmacologic, not hepatic failure; albumin 4.0 g/dL confirms preserved synthetic function
D) Factor V level is unreliable in patients on warfarin and should not be used
Correct Answer: C
Teaching Point 3 Verified: In anticoagulated patients, INR is not a measure of hepatic synthetic function. An INR of 4.0 on warfarin is pharmacologic, not hepatic failure. Assess albumin, total protein, and factor V for synthetic function. Factor V is NOT affected by warfarin (it is not vitamin K-dependent) and can serve as a true marker of hepatic synthetic capacity.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
Teaching Point 3 Verified: In anticoagulated patients, INR is not a measure of hepatic synthetic function. An INR of 4.0 on warfarin is pharmacologic, not hepatic failure. Assess albumin, total protein, and factor V for synthetic function. Factor V is NOT affected by warfarin (it is not vitamin K-dependent) and can serve as a true marker of hepatic synthetic capacity.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
17
A patient with CKD Stage 4 (eGFR 22) has free kappa 95 mg/L and free lambda 11 mg/L (ratio 8.6). Using the iStopMM framework, which interpretation is correct?
A) Both values are elevated from CKD -- no further workup needed
B) The absolute values are elevated from CKD, but the ratio of 8.6 is far above the eGFR-adjusted upper limit and indicates kappa clonal excess requiring investigation
C) The kappa value alone is diagnostic of myeloma
D) Only the lambda value matters because lambda is the cardiotrophic light chain
Correct Answer: B
Teaching Points 5-6 Verified: The two-rule framework: Rule 1 -- Look at the ratio, not the absolutes. Apply the iStopMM eGFR-adjusted interval. An absolute kappa of 95 mg/L in Stage 4 CKD is physiologic noise. A ratio of 8.6 in the same patient is clonal signal. Rule 2 -- If the ratio is abnormal, determine the direction and magnitude. High ratio = kappa excess; low ratio = lambda excess. Either direction demands clonal investigation regardless of absolute values.
📚 Learn More: Monoclonal Protein Interpretation for the Nephrologist
Teaching Points 5-6 Verified: The two-rule framework: Rule 1 -- Look at the ratio, not the absolutes. Apply the iStopMM eGFR-adjusted interval. An absolute kappa of 95 mg/L in Stage 4 CKD is physiologic noise. A ratio of 8.6 in the same patient is clonal signal. Rule 2 -- If the ratio is abnormal, determine the direction and magnitude. High ratio = kappa excess; low ratio = lambda excess. Either direction demands clonal investigation regardless of absolute values.
📚 Learn More: Monoclonal Protein Interpretation for the Nephrologist
18
A colleague states: "This patient cannot have AL amyloidosis because there is no nephrotic syndrome." Which response BEST addresses this reasoning error?
A) "You are correct -- AL amyloidosis always involves the kidney with heavy proteinuria"
B) "Nephrotic syndrome is not always present, but at least microalbuminuria should be detectable"
C) "20-30% of AL patients present with cardiac-predominant disease and minimal renal involvement; lambda V-lambda-1/6 segments target myocardium and spare glomerulus. The FLC assay should be ordered regardless of nephrotic syndrome status."
D) "Only ATTR amyloidosis presents without nephrotic syndrome; AL always has renal involvement"
Correct Answer: C
Teaching Points 7-8 Verified: The absence of nephrotic syndrome was cited at multiple points as evidence against AL amyloidosis in Patient A's care. This heuristic is incorrect and potentially lethal. Lambda light chains encoded by V-lambda-1 and V-lambda-6 segments preferentially target the myocardium and spare the glomerulus. The FLC assay and monoclonal protein screen should be ordered whenever cardiac amyloidosis is in the differential -- without requirement for nephrotic syndrome.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
Teaching Points 7-8 Verified: The absence of nephrotic syndrome was cited at multiple points as evidence against AL amyloidosis in Patient A's care. This heuristic is incorrect and potentially lethal. Lambda light chains encoded by V-lambda-1 and V-lambda-6 segments preferentially target the myocardium and spare the glomerulus. The FLC assay and monoclonal protein screen should be ordered whenever cardiac amyloidosis is in the differential -- without requirement for nephrotic syndrome.
📚 Learn More: Cardiac-Predominant AL Amyloidosis
8 Teaching Points Summary
Teaching Point 1 -- The Preserved EF Trap: Ejection fraction is a fraction, not a measure of cardiac output. In infiltrative cardiomyopathy, a preserved EF coexists with critically reduced stroke volume. When clinical severity exceeds echo reassurance, right heart catheterization is the appropriate next step.
Teaching Point 2 -- Cardiac Pseudo-Cirrhosis: Congestive hepatopathy from elevated right-sided filling pressures produces CT findings indistinguishable from cirrhosis. When there are no risk factors for liver disease and synthetic function is preserved (albumin >= 3.5 g/dL), question the radiographic diagnosis. High-protein ascites (>= 2.5 g/dL) with SAAG >= 1.1 indicates intact sinusoidal fenestrations and cardiac etiology.
Teaching Point 3 -- Warfarin and INR: In anticoagulated patients, INR is not a measure of hepatic synthetic function. An INR of 4.0 on warfarin is pharmacologic, not hepatic failure. Assess albumin, total protein, and factor V for synthetic function.
Teaching Point 4 -- AL vs. ATTR Algorithm: PYP scintigraphy cannot be interpreted without simultaneous monoclonal protein exclusion. A positive PYP in a patient with a monoclonal protein requires tissue biopsy with mass spectrometry. The most dangerous error is diagnosing ATTR on PYP alone and prescribing tafamidis for AL amyloidosis.
Teaching Point 5 -- Two Tests, Two Questions: The serum FLC ratio is the primary screening tool for AL amyloidosis. The monoclonal protein screen (SPEP/immunofixation/MASS-FIX) is the primary tool for MGUS/MGRS/myeloma. In AL amyloidosis, the M-protein may be undetectable. Ordering SPEP alone does not screen adequately for AL amyloidosis.
Teaching Point 6 -- FLC Ratio in CKD: Absolute FLC values are physiologically elevated in CKD. The kappa/lambda ratio, corrected for eGFR using the iStopMM reference intervals, is the diagnostic metric. A ratio of 0.1863 in CKD Stage 4 is not explainable by renal physiology and demands clonal investigation.
Teaching Point 7 -- Lambda Cardiotrophic AL Without Nephrotic Syndrome: Approximately 20-30% of AL patients present with cardiac-predominant disease and minimal renal involvement. Lambda light chains encoded by V-lambda-1 and V-lambda-6 segments preferentially target the myocardium and spare the glomerulus. Absence of nephrotic syndrome should not lower suspicion.
Teaching Point 8 -- Diagnostic Urgency: In Stage III-IV AL cardiac amyloidosis, the therapeutic window is measured in weeks. The complete amyloid workup (FLC, immunofixation, PYP scintigraphy, NT-proBNP, troponin) must be ordered simultaneously and urgently -- not sequentially. Diagnostic delay at this stage is lethal.
Integration Challenge: Multi-System Synthesis
These questions require integration across cardiac, hepatic, renal, and hematologic systems.
19
Patient A has CI 1.15, RA 23 mmHg, eGFR <30, mild proteinuria (protein/creatinine ratio 0.73), and no peripheral edema despite massive ascites. Which integrated pathophysiologic explanation BEST accounts for ALL of these findings?
A) Primary cirrhosis causing portal hypertension with hepatorenal syndrome and secondary cardiac dysfunction
B) Primary nephrotic syndrome causing volume overload with compensatory cardiac hypertrophy and hepatic congestion
C) Lambda cardiotrophic AL amyloidosis causing infiltrative cardiomyopathy (CI 1.15), transmitted venous congestion to liver (RA 23, pseudo-cirrhosis, preferential splanchnic ascites), cardiorenal syndrome Type 1 (hemodynamic CKD), and subclinical glomerular involvement (mild proteinuria)
D) ATTR cardiac amyloidosis with coincidental CKD and NASH cirrhosis
Correct Answer: C
Learning Point: This case demonstrates the power of a unifying diagnosis. Lambda cardiotrophic AL amyloidosis explains every finding through a single pathophysiologic mechanism: (1) Cardiac: Amyloid infiltration causes restrictive physiology with preserved EF but shock-range CI; (2) Hepatic: RA 23 mmHg transmits to hepatic veins causing congestive hepatopathy and pseudo-cirrhosis; (3) Ascites without edema: Preferential splanchnic transudation through intact sinusoidal fenestrations; (4) Renal: Cardiorenal syndrome Type 1 (low output + venous congestion) plus subclinical glomerular involvement; (5) Hematologic: Lambda clone producing cardiotrophic light chains.
📚 Learn More: Cardiac Amyloidosis Diagnostic Challenges
Learning Point: This case demonstrates the power of a unifying diagnosis. Lambda cardiotrophic AL amyloidosis explains every finding through a single pathophysiologic mechanism: (1) Cardiac: Amyloid infiltration causes restrictive physiology with preserved EF but shock-range CI; (2) Hepatic: RA 23 mmHg transmits to hepatic veins causing congestive hepatopathy and pseudo-cirrhosis; (3) Ascites without edema: Preferential splanchnic transudation through intact sinusoidal fenestrations; (4) Renal: Cardiorenal syndrome Type 1 (low output + venous congestion) plus subclinical glomerular involvement; (5) Hematologic: Lambda clone producing cardiotrophic light chains.
📚 Learn More: Cardiac Amyloidosis Diagnostic Challenges
20
Patient A's PCWP-RVEDP gradient is +3 mmHg (28 - 25), placing it in the "equalization zone." The PCWP-RVEDP gradient direction (left > right) is used to differentiate restriction from constriction. Which statement about this patient's hemodynamics is CORRECT?
A) The near-equalization proves constrictive pericarditis; pericardial stripping should be considered
B) The gradient is too narrow to be diagnostically useful and should be ignored
C) The direction (PCWP > RVEDP) favors restriction over constriction; the narrow gap reflects advanced biventricular amyloid infiltration bringing filling pressures into near-parity from their respective burdens
D) A gradient of +3 mmHg definitively excludes constrictive pericarditis
Correct Answer: C
Learning Point: In restriction, PCWP typically exceeds RVEDP (left > right) because the left ventricle is preferentially affected by infiltration. In constriction, filling pressures equalize because the rigid pericardium constrains both ventricles equally. Here, the direction (left > right, +3 mmHg) favors restriction, but the narrow gap reflects advanced biventricular amyloid infiltration -- both ventricles are heavily involved, bringing filling pressures into near-parity from their respective amyloid burdens rather than from pericardial constraint.
📚 Learn More: Restrictive vs Constrictive Physiology
Learning Point: In restriction, PCWP typically exceeds RVEDP (left > right) because the left ventricle is preferentially affected by infiltration. In constriction, filling pressures equalize because the rigid pericardium constrains both ventricles equally. Here, the direction (left > right, +3 mmHg) favors restriction, but the narrow gap reflects advanced biventricular amyloid infiltration -- both ventricles are heavily involved, bringing filling pressures into near-parity from their respective amyloid burdens rather than from pericardial constraint.
📚 Learn More: Restrictive vs Constrictive Physiology
Diagnosis and Clinical Outcome
Technetium-99m pyrophosphate scintigraphy: Grade 0 uptake -- effectively excluding ATTR-CM.
The combination of positive lambda monoclonal screen + negative PYP scintigraphy established the diagnosis: AL (lambda) cardiac amyloidosis.
Patient A was referred for hematology consultation and staged for bone marrow evaluation. The patient died from sudden cardiac arrest during staging PET scanning before disease-modifying therapy could be initiated.
The Fatal Compression: The time between initial presentation and diagnostic confirmation was consumed by sequential rather than parallel diagnostic steps: referral for PYP scintigraphy, awaiting FLC results, hepatology consultation, cardiology RHC, hematology scheduling. In Stage III-IV AL cardiac amyloidosis, the therapeutic window is measured in weeks. Sequential ordering at this stage is not merely inefficient -- it is lethal.
References
- Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update. Am J Hematol. 2024;99(2):309-324.
- Ladefoged B, et al. Diagnostic delay in wild type transthyretin cardiac amyloidosis. Int J Cardiol. 2020;304:138-143.
- Quarta CC, et al. AL amyloidosis for cardiologists. JACC CardioOncol. 2022;4(4):427-441.
- Thorsteinsdottir S, et al. Defining new FLC reference intervals in CKD: iStopMM. Blood Cancer J. 2022;12(9):133.
- Gillmore JD, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412.
- Kastritis E, et al. Daratumumab-based treatment for AL amyloidosis (ANDROMEDA). N Engl J Med. 2021;385(1):46-58.
- Comenzo RL, et al. Tropism of organ involvement in primary systemic amyloidosis. Blood. 2001;98(3):714-720.
- Kumar S, et al. Revised prognostic staging for AL amyloidosis. J Clin Oncol. 2012;30(9):989-995.
- Kittleson MM, et al. 2023 ACC Expert Consensus on Cardiac Amyloidosis. JACC. 2023;81(11):1076-1126.
- Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology. 2009;49(6):2087-2107.
- Dispenzieri A, et al. IMWG guidelines for serum-free light chain analysis. Leukemia. 2009;23(2):215-224.
Case Reflection and Multi-Module Integration
RHC Module Integration
- Forrester classification application
- CI calculation and shock thresholds
- PH classification (Group 2 CpcPH)
- PCWP-RVEDP gradient interpretation
- Preserved EF trap recognition
Cardiac Amyloidosis Integration
- AL vs ATTR differentiation algorithm
- PYP scintigraphy interpretation rules
- Gillmore nonbiopsy diagnostic criteria
- Lambda cardiotrophic tissue tropism
- Mayo 2012 staging thresholds
Paraprotein Evaluation Integration
- FLC ratio vs absolute values in CKD
- iStopMM eGFR-adjusted reference intervals
- Two tests, two questions framework
- SPEP sensitivity limitations in AL
- dFLC and Mayo staging thresholds
Restrictive vs Constrictive Integration
- PCWP-RVEDP gradient direction
- Equalization zone interpretation
- Biventricular infiltration hemodynamics
- Clinical context in pressure analysis
Key Integration Concepts
This case demonstrates how a single unifying diagnosis -- lambda cardiotrophic AL amyloidosis -- explains findings across four organ systems. The systematic approach requires integration of hemodynamic interpretation (RHC), ascites evaluation (hepatology), monoclonal protein screening (hematology), and renal physiology (nephrology). Real clinical excellence comes from recognizing the four diagnostic traps and ordering the complete workup simultaneously.
Cardiac Integration
Preserved EF with shock-range CI; Forrester C hemodynamics; Group 2 CpcPH; restrictive physiology
Hepatic Integration
Pseudo-cirrhosis from RA 23 mmHg; high-protein cardiac ascites; preferential splanchnic transudation
Renal Integration
Cardiorenal syndrome Type 1; FLC ratio in CKD; iStopMM framework; subclinical glomerular involvement
Hematologic Integration
Lambda AL clone; V-lambda-1/6 cardiac tropism; dFLC staging; diagnostic urgency in Stage III-IV
Case Summary and Clinical Pearls
This case exemplifies lambda cardiotrophic AL amyloidosis presenting as refractory ascites with four converging diagnostic traps: preserved EF masking cardiogenic shock, cardiac pseudo-cirrhosis on CT, absence of nephrotic syndrome, and FLC values dismissed as CKD artifact. Patient A died before therapy could be initiated -- a consequence of sequential rather than parallel diagnostic ordering.
Key Clinical Pearls from This Case:
- The EF Trap: EF 55% + CI 1.15 = cardiogenic shock with preserved fraction of inadequate volume
- The Ascites Signal: SAAG >= 1.1 + fluid protein >= 2.5 + albumin 4.0 = cardiac, not cirrhotic
- The Ratio Rule: FLC ratio survives CKD; absolutes do not. Apply iStopMM-adjusted intervals.
- The Two-Test Rule: FLC ratio screens for AL; SPEP/IFE screens for MGUS/myeloma. They are not interchangeable.
- Diagnostic Urgency: In Stage III-IV AL, parallel ordering is mandatory. Sequential ordering is lethal.